In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair ...

The table below is a review of notable updates that occurred in May 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Even if you live far from the boreal forests in Canada and Siberia, you've likely noticed an increase in smoke from their forest fires. During major blazes in 2023, the smoke tinted the New York ...

ASCO 2025 Which Tx Combo Is Best for HER2+ Breast Cancer? Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive metastatic breast ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.

The losses include millions of dollars the NIH has already spent on research that will no longer generate results, and the next generation of scientists whose work has been cut short.

At the beginning of the study, people who scored higher for adherence to MIND had a 9% lower risk of developing dementia. The amount of reduction varied among the racial groups in the new analysis.

CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer ...

In the landmark CLEOPATRA study (NCT00567190), THP significantly improved median overall survival (OS) from 40.8 months (95% CI, 35.8-48.3) with placebo, trastuzumab, and docetaxel to 56.5 months ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast ...

In the multicenter, open-label DESTINY-Breast09 study, patients with HER2-positive metastatic or advanced breast cancer were randomly assigned 1:1:1 to receive Enhertu at 5.4 milligram per kilogram ...

A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday.